Medovex Corporation to Participate in World's Largest Spine Exhibition, NASS 2015

By CIOReview | Friday, September 11, 2015
875
1462
267

ATLANTA, GA:  Medovex, a developer of medical technology products, announces that the Company will be participating in NASS 2015, being held in Chicago, October 14-17, 2015. The North American Spine Society ("NASS") is a one of a kind annual meeting where spine care professionals from around the globe will share the latest information, innovative techniques and procedures, best practices, and new technologies.

As part of the Company's pre-launch strategy, Medovex will host a Surgical Innovation Lab with leading European and U.S. spine surgeons at the NASS meeting. Dr. Scott Haufe M.D. and members of the Company's Executive team, will be demonstrating the Company's DenerveX System technology, as well as hosting a private business suite to meet with key opinion leaders from Europe and the U.S.

The Company's patented DenerveX System, currently in development and not yet commercially available, is designed to provide relief of pain associated with the facet joint. Lower back pain is the second most common cause of disability in the U.S. for adults. Studies indicate that 10 percent of the U.S. adult population suffers from lower back pain and that 31 percent of lower back pain is attributed to facet joint pain.

The DenerveX System consists of the DenerveX device, a single use device, and the DenerveX Pro-40 Power Generator. The DenerveX system is designed to provide a minimally invasive treatment option which combines two actions into one device. The combined procedure is expected to provide a longer lasting solution and potential savings to the health care system.

Mr. Patrick Kullmann, Medovex President and COO, states, "We are excited to be participating in NASS 2015, as well as hosting a Surgical Innovation Lab with Dr. Haufe for these leading spine surgeons. The purpose of the Surgical Innovation Lab is to provide a training experience as part of our pre-European market launch activities by inviting members of our clinical advisory board and some of the leading European and U.S. based key opinion leaders.

Kullmann continues, "It's a single location to meet with others from around the globe to collaborate, hear differing perspectives, develop relationships and interact with practitioners from other specialties, something we view as very important as we continue to proceed in the later stages of the development of our DenerveX technology and begin the pre-launch process. This lab, along with the identification of distribution partners, will prepare us well for our future launch outside the U.S."